Chicago Equity Partners’s Novavax NVAX Stock Holding History

Chicago Equity Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,378	Closed	-$713K	–	897
2018 Q4	$713K	Sell	19,378 -18,674	-49%	-$724K	0.03%	553
2018 Q3	$1.43M	Hold	38,052	–	–	0.04%	451
2018 Q2	$1.02M	Sell	38,052 -3,436	-8%	-$116K	0.03%	518
2018 Q1	$1.74M	Sell	41,488 -4,557	-10%	-$183K	0.06%	398
2017 Q4	$1.14M	Sell	46,045 -7,370	-14%	-$180K	0.03%	475
2017 Q3	$1.22M	Sell	53,415 -27,088	-34%	-$606K	0.04%	472
2017 Q2	$1.85M	Buy	+80,503	New	+$1.58M	0.05%	384

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Chicago Equity Partners's NVAX Position: Q1 2019 in Review

Chicago Equity Partners sold out of Novavax (NVAX) in Q1 2019, closing a stake of 19,378 shares — an estimated $713K sold.

Chicago Equity Partners first reported a position in NVAX in Q2 2017 and held it in 7 quarters. The position peaked at $1.85M in Q2 2017. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

Chicago Equity Partners reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
Chicago Equity Partners sold 19,378 Novavax shares in Q1 2019, an estimated $713K.
Chicago Equity Partners first reported a position in Novavax in Q2 2017 and held it in 7 quarters.
Chicago Equity Partners's Novavax position peaked at $1.85M in Q2 2017.
140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Chicago Equity Partners's 13F filing for Q1 2019, filed 14 May 2019.